Cargando…

Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course

BACKGROUND: Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS. MOGAD can present with a monophasic or relapsing disease course with distinct clinical manifestations.However, data on the disease course an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rechtman, Ariel, Brill, Livnat, Zveik, Omri, Uliel, Benjamin, Haham, Nitzan, Bick, Atira S., Levin, Netta, Vaknin-Dembinsky, Adi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987978/ https://www.ncbi.nlm.nih.gov/pubmed/35401390 http://dx.doi.org/10.3389/fneur.2022.867190

Ejemplares similares

Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis
por: Brill, Livnat, et al.
Publicado: (2022)

Sera of Neuromyelitis Optica Patients Increase BID-Mediated Apoptosis in Astrocytes
por: Zveik, Omri, et al.
Publicado: (2022)

Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells
por: Zveik, Omri, et al.
Publicado: (2022)

Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine()
por: Brill, Livnat, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Brill, Livnat, et al.
Publicado: (2022)

Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel
por: Brill, Livnat, et al.
Publicado: (2021)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis
por: Lavon, Iris, et al.
Publicado: (2019)

Description of 3 patients with myasthenia gravis and COVID-19
por: Rein, Netaniel, et al.
Publicado: (2020)

Editorial: MOGAD, current knowledge and future trends
por: Siritho, Sasitorn, et al.
Publicado: (2023)

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
por: Vaknin-Dembinsky, Adi, et al.
Publicado: (2016)

NMOSD and MOGAD Dual Positivity: An Extremely Rare Phenomenon
por: Agarwal, Ayush, et al.
Publicado: (2022)

Attack phenotypes and disease course in pediatric MOGAD
por: Santoro, Jonathan D., et al.
Publicado: (2023)

NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness
por: Mizrachi, Tehila, et al.
Publicado: (2018)

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies
por: Asseyer, Susanna, et al.
Publicado: (2020)

Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD
por: Nosadini, Margherita, et al.
Publicado: (2022)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

Clinical Profile and Treatment Outcome in MOGAD: A Single-Center Case-Series Study in Guiyang, China
por: Lei, Xiaoyang, et al.
Publicado: (2022)

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges
por: Al-Ani, Abdullah, et al.
Publicado: (2023)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management
por: Sechi, Elia, et al.
Publicado: (2022)

The imprint of childhood adversity on emotional processing in high functioning young adults
por: Mirman, Aron, et al.
Publicado: (2020)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
por: Sen, Sedat, et al.
Publicado: (2022)

Neuroinflammation Modulation via α7 Nicotinic Acetylcholine Receptor and Its Chaperone, RIC-3
por: Mizrachi, Tehila, et al.
Publicado: (2021)

Clinical and neuroimaging findings in MOGAD–MRI and OCT
por: Bartels, Frederik, et al.
Publicado: (2021)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

Volumetric Reductions of Subcortical Structures and Their Localizations in Alcohol-Dependent Patients
por: Shim, Jae-Hyuk, et al.
Publicado: (2019)

Three-Dimensional Volumetric Measurement of Endolymphatic Hydrops in Meniere's Disease
por: Noh, Tae-Soo, et al.
Publicado: (2021)

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review
por: Kinnunen, Kirsi M., et al.
Publicado: (2021)

MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity
por: Yandamuri, Soumya S., et al.
Publicado: (2023)

Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials
por: Kinnunen, Kirsi M., et al.
Publicado: (2021)

Inhibition of Effector Function but Not T Cell Activation and Increase in FoxP3 Expression in T Cells Differentiated in the Presence of PP14
por: Ochanuna, Zohar, et al.
Publicado: (2010)

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis
por: Statsenko, Yauhen, et al.
Publicado: (2023)

Neurodevelopmental outcomes and volumetric analysis of brain in preterm infants with isolated cerebellar hemorrhage
por: Kim, Seh Hyun, et al.
Publicado: (2022)

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
por: Graf, Jonas, et al.
Publicado: (2020)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
por: Derdelinckx, Judith, et al.
Publicado: (2021)

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade
por: Yong, Kok Pin, et al.
Publicado: (2021)

The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON
por: Yao, Yajun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hnb13v3ijq4d1l392mjapfsas9